HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe

Topical Oxygen Is an Effective Treatment for Recalcitrant Ulcers

May 23, 2018 by Joshua Bolkan

A new study finds that topical wound oxygen (TWO2) is an effective treatment for recalcitrant ulcers.
The study, "A Retrospective Review of Pressurized Cyclical Topical Oxygen as an Adjunct Treatment in Healing Chronic Wounds and Ulcerations," was a two-year retrospective review of the treatment of 71 patients at a Veterans Affairs hospital with 115 wounds between them. Each of the patients was prescribed at-home treatment with cyclical pressurized TWO2. The wound types included "a mix of venous/lymphatic insufficiency ulcers, surgical and traumatic wounds, diabetic ulcers, pressure ulcers and ischemic ulcers," according to a news release. "Additionally, most patients had concurrent peripheral vascular disease."

After two years, the researchers found that nearly two-thirds, 64.4 percent, of the 115 ulcers tracked for the study had completely closed and the majority of the remaining ulcers had decreased in size since beginning oxygen treatment. The study’s authors also noted that "a number" of study subjects reported pain reduction associated with the oxygen treatment.

"We are delighted to see further scientific evidence supporting the effectiveness of our unique multi-modality TWO2 therapy in healing chronic ulcerations being presented at both the SAWC and EWMA conferences, which are the largest annual multi-disciplinary wound care conferences held in the USA and Europe respectively," said Mike Griffiths, CEO and president of AOTI, in a prepared statement. "AOTI remains committed to fostering the development of the strongest scientific evidence demonstrating both the healing and health economic benefits of our patented topical wound oxygen homecare therapy."

An abstract of the study is available at ewma.conference2web.com.

Related Articles Read More >

Drive Medical Names Head of Respiratory Clinical Affairs & Industry Relations
Chrysalis Ashton has a long history of education and industry advocacy.
Voting Now Open For the HME Business Product of the Year Awards
Cast your votes for your favorite products, solutions, and technologies by September 30
From the Editor: I’ll Meet You in Austin!
Join HME Business and Home Health Care News for the FUTURE conference later this month.
Drive Medical Launches Tech-Enabled Unbound IQ Brand
The series kicks off with two systems for mobility aids.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
    • FUTURE Conference
  • Awards
  • Advertise
  • Subscribe